Nippon Shinyaku Co., Ltd., founded in 1678 and headquartered in Kyoto, Japan, is a research‐driven pharmaceutical company specializing in the development, manufacturing and marketing of prescription and over‐the‐counter drugs. The company’s early roots in traditional medicines have evolved into a modern operation that spans discovery research, clinical development and commercial supply chains. Through its long history, Nippon Shinyaku has built a foundation of proprietary small‐molecule platforms and formulation technologies.
The company’s core therapeutic areas include urology, hematology, oncology, central nervous system disorders, lifestyle diseases such as diabetes and cardiovascular conditions, and infectious diseases. Key marketed products include anticoagulants for stroke prevention, oral hemostatics for bleeding disorders and symptomatic treatments for urological conditions. In addition to pharmaceuticals, Nippon Shinyaku produces functional ingredients for food and cosmetic applications, leveraging its expertise in chemical synthesis and formulation.
Nippon Shinyaku maintains research and manufacturing facilities in Japan and has established subsidiaries and partnerships in North America, Europe and Asia to support global clinical trials and product distribution. The company invests a significant portion of revenues into R&D, pursuing novel small molecules and biologics in collaboration with academic institutions and international pharmaceutical partners. Governed by a board of directors and led by its president and executive team in Kyoto, Nippon Shinyaku continues to expand its global footprint while upholding a legacy of innovation that spans more than three centuries.
AI Generated. May Contain Errors.